In cancer genetics and precision oncology, this addresses germline cancer-susceptibility gene testing beyond the two most well-characterized genes: patients who develop multiple primary cancers show a higher rate of pathogenic mutations across a panel of cancer-susceptibility genes than patients with a single primary cancer, independent of age at onset for cancers other than the first. This supports the principle that multi-gene panel testing, rather than testing restricted to a small number of high-profile genes or gated by age criteria, should be used to identify hereditary cancer risk in patients with multiple primary malignancies, with genes further distinguishable by penetrance (high- versus moderate-penetrance) and by their differential enrichment in early-onset versus familial cancer patterns.
In cancer genetics and precision oncology, this addresses germline cancer-susceptibility gene testing beyond the two most well-characterized genes: patients who develop multiple primary cancers show …